The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.
The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
On the last trading day of 2025, Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across ...
Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...
The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...
Jarez Holz says 2026 will be a strong year for biotech stocks. The Mizuho analyst explained why in a recent CNBC interview.
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...
There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...
After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.
Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...